Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib : Characterization, In Vitro Drug Release, and In Vivo Studies
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved..
Celecoxib (CXB) is a widely used anti-inflammatory drug that also acts as a chemopreventive agent against several types of cancer, including skin cancer. As the long-term oral administration of CXB has been associated with severe side effects, the skin delivery of this drug represents a promising alternative for the treatment of skin inflammatory conditions and chemoprevention of skin cancer. We prepared and characterized liquid crystalline systems based on glyceryl monooleate and water containing penetration enhancers which were primarily designed to promote skin delivery of CXB. Analysis of their phase behavior revealed the formation of cubic and hexagonal phases depending on the systems' composition. The systems' structure and composition markedly affected the in vitro CXB release profile. Oleic acid reduced CXB release rate, but association oleic acid/propylene glycol increased the drug release rate. The developed systems significantly reduced inflammation in an aerosil-induced rat paw edema model. The systems' composition and liquid crystalline structure influenced their anti-inflammatory potency. Cubic phase systems containing oleic acid/propylene glycol association reduced edema in a sustained manner, indicating that they modulate CXB release and permeation. Our findings demonstrate that the developed liquid crystalline systems are potential carriers for the skin delivery of CXB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical sciences - 107(2018), 3 vom: 01. März, Seite 870-878 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dante, Mariane de Cássia Lima [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.09.2018 Date Revised 12.09.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xphs.2017.10.039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM27775853X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM27775853X | ||
| 003 | DE-627 | ||
| 005 | 20231225015012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xphs.2017.10.039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0925.xml |
| 035 | |a (DE-627)NLM27775853X | ||
| 035 | |a (NLM)29108729 | ||
| 035 | |a (PII)S0022-3549(17)30778-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dante, Mariane de Cássia Lima |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib |b Characterization, In Vitro Drug Release, and In Vivo Studies |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.09.2018 | ||
| 500 | |a Date Revised 12.09.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Celecoxib (CXB) is a widely used anti-inflammatory drug that also acts as a chemopreventive agent against several types of cancer, including skin cancer. As the long-term oral administration of CXB has been associated with severe side effects, the skin delivery of this drug represents a promising alternative for the treatment of skin inflammatory conditions and chemoprevention of skin cancer. We prepared and characterized liquid crystalline systems based on glyceryl monooleate and water containing penetration enhancers which were primarily designed to promote skin delivery of CXB. Analysis of their phase behavior revealed the formation of cubic and hexagonal phases depending on the systems' composition. The systems' structure and composition markedly affected the in vitro CXB release profile. Oleic acid reduced CXB release rate, but association oleic acid/propylene glycol increased the drug release rate. The developed systems significantly reduced inflammation in an aerosil-induced rat paw edema model. The systems' composition and liquid crystalline structure influenced their anti-inflammatory potency. Cubic phase systems containing oleic acid/propylene glycol association reduced edema in a sustained manner, indicating that they modulate CXB release and permeation. Our findings demonstrate that the developed liquid crystalline systems are potential carriers for the skin delivery of CXB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a controlled delivery | |
| 650 | 4 | |a lipids | |
| 650 | 4 | |a permeation enhancers | |
| 650 | 4 | |a skin | |
| 650 | 4 | |a transdermal drug delivery | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Glycerides |2 NLM | |
| 650 | 7 | |a Water |2 NLM | |
| 650 | 7 | |a 059QF0KO0R |2 NLM | |
| 650 | 7 | |a Oleic Acid |2 NLM | |
| 650 | 7 | |a 2UMI9U37CP |2 NLM | |
| 650 | 7 | |a Propylene Glycol |2 NLM | |
| 650 | 7 | |a 6DC9Q167V3 |2 NLM | |
| 650 | 7 | |a monoolein |2 NLM | |
| 650 | 7 | |a C4YAD5F5G6 |2 NLM | |
| 650 | 7 | |a Celecoxib |2 NLM | |
| 650 | 7 | |a JCX84Q7J1L |2 NLM | |
| 700 | 1 | |a Borgheti-Cardoso, Livia Neves |e verfasserin |4 aut | |
| 700 | 1 | |a Fantini, Marcia Carvalho de Abreu |e verfasserin |4 aut | |
| 700 | 1 | |a Praça, Fabíola Silva Garcia |e verfasserin |4 aut | |
| 700 | 1 | |a Medina, Wanessa Silva Garcia |e verfasserin |4 aut | |
| 700 | 1 | |a Pierre, Maria Bernadete Riemma |e verfasserin |4 aut | |
| 700 | 1 | |a Lara, Marilisa Guimarães |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical sciences |d 1961 |g 107(2018), 3 vom: 01. März, Seite 870-878 |w (DE-627)NLM000006394 |x 1520-6017 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2018 |g number:3 |g day:01 |g month:03 |g pages:870-878 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xphs.2017.10.039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2018 |e 3 |b 01 |c 03 |h 870-878 | ||